



**Midwest
Hemophilia
Association**

2021 WELCOME!

YOU BELONG HERE

– with the 29th Annual –
Family Education Weekend
September 25-26, 2021

1471 W. South Street, Suite F • Ozark, MO 65721
info@midwesthemophilia.org

MidwestHemophilia.org



esperoct[®]
*antihemophilic factor (recombinant),
glycopegylated-exei*

Discover more at **esperoct.com.**

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

Esperoct[®] is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2020 Novo Nordisk Printed in the USA. US19ESP00186 February 2020



2021 WELCOME! YOU BELONG HERE

TABLE OF CONTENTS

Welcome Letter	4
Board of Directors	5
Fundraising Events:	
Unite for Bleeding Disorders.....	6
Fundraising Events:	
Annual Golf Tournament & Trivia Night.....	7
Educational Events:	
Summer Camp.....	8
Educational Events:	
Community Outreach & Education Days.....	9
Community Support:	
Advocacy.....	10
Community Support:	
Scholarships.....	11
Community Resource:	
Financial Assistance Program.....	12 - 13
2021 Unite for Bleeding Disorders Walk.....	14 - 15
Family Education Agenda.....	16-17
Family Education Weekend Sponsors.....	18-19
2020 Annual Report.....	20

Welcome

to the Midwest Hemophilia Association family! We believe you belong here. This brochure is intended to provide readers with a brief snapshot, a sort of family album, of our advocacy efforts, education programs, fundraising endeavors, the resources available to our bleeding disorders community and opportunities for you to get involved. Please browse through the pages and keep it as a reference tool to stay connected.

Brief History. Founded in 1991, the Midwest Hemophilia Association (MHA), a 501©3 non-profit, serves individuals and families in Kansas and Western Missouri with hemophilia, von Willebrand disease, and other bleeding disorders. Our mission is to improve the quality of life for those affected by bleeding disorders through advocacy, education, and support. We currently offer a range of programs and services made possible through the generosity of individuals, corporations, and foundations with the belief that our mission to improve the quality of life, can also prevent disability and enable persons to live active, fulfilling lives.

What is a bleeding disorders? A bleeding disorder is a genetic blood clotting deficiency caused by the absence or inactivity of an essential blood clotting protein, or "factor." This deficiency causes the body to form unstable blood clots that allow bleeding to continue longer than normal.

A person with a bleeding disorder can experience frequent and often spontaneous episodes of prolonged bleeding. The most severe cases can have extensive bleeding into joints, muscles, and vital organs, resulting in life-threatening emergencies and crippling long-term complications.

Hemophilia and related bleeding disorders, such as von Willebrand disease, are genetically inherited. However, one in three diagnosed cases of hemophilia results from a spontaneous genetic mutation where there is no family history of abnormal bleeding.

What is the treatment? Hemophilia treatment includes replacing the missing blood clotting factor so the blood can clot properly, typically done by injecting treatment products, called factor concentrates. Prophylactic care is recommended by the CDC and most clinicians to prevent bleeding episodes from occurring. It is possible for individuals and families to learn how to give their own factor clotting treatment products at home, resulting often in quicker treatment and less serious bleeding and fewer side effects. The kind of treatment for von Willebrand disease depends on the type and severity, but may include nasal spray, birth control, antifibrinolytic drugs, and/or factor replacement therapy.

2021 Board of Directors

EXECUTIVE DIRECTOR



ANGELA BROWN

angela.brown@midwesthemophilia.org

BOARD OF DIRECTORS OFFICERS



NORA ANCEL
PRESIDENT

nora.e.ancel@gmail.com



BRIDGET CASTRO
VICE PRESIDENT


brdgt_c@yahoo.com



MAREENA SNAREY
TREASURER

treasurer@midwesthemophilia.org

BOARD OF DIRECTORS MEMBERS



HEATHER INCE

Hince2013@gmail.com



DAKOTA ROSENFELT

DakotaRosenfelt@me.com



KIM ROSENFELT

KRosenfelt@hotmail.com



CODY YORK

Cyxq6@mail.umkc.edu

UNITE FOR BLEEDING DISORDERS

The UNITE for Bleeding Disorders walk is an annual nationwide event held throughout the year in over 40 cities in the U.S. to raise funds and awareness for bleeding disorders.

The MHA chapter hosts our UNITE for Bleeding Disorders fundraiser in the Kansas City area bringing together the bleeding disorders community and their supporters to raise crucial funds for our organization. 100% of the donations raised go directly to MHA's services and programs which help us meet our mission to improve the quality of life for those affected by bleeding disorders with education, advocacy, resources, and support!

The 2021 UNITE for Bleeding Disorder walk will take place Saturday, October 16, 2021, at Heritage Park, Shelter #1, 10650 S. Pflumm Rd, Olathe, KS 66026 from 10am-1pm with top team and individual recognitions, fundraising prizes, raffles, food, games & activities for the whole family. We welcome family, friends, neighbors, co-workers, teachers, coaches, leaders of our community and the general public to join us in our efforts! We also gladly accept individual and/or business sponsorships.

To register and donate to 2021's walk, scan the QR code on page 15 or visit midwesthemophilia.org/events/.

We also gladly accept individual and business sponsorships. For sponsorship inquiries for the 2021 OR 2022 walk please contact us at 816-479-5900 or info@midwesthemophilia.org.



ANNUAL GOLF TOURNAMENT & TRIVIA NIGHT

In it's 23rd year, MHA's Annual Golf Tournament continues to be a consistent source of revenue and support of our mission thanks to generous sponsors and both new and returning golf teams and players. Open to the public or anyone who believes in helping people with a chronic illness improve their quality of life, we host up to 36 teams on the beautiful Winterstone Golf Course in Independence, Missouri. The tournament format is a flighted, 18-hole, four-person scramble with a shotgun start. Golfers compete for team and individual prizes, including a \$10,000 Hole-In-One Cash Prize! Other hole contests and raffles optional.

To sponsor, play or serve on the golf committee in September 2022, please contact us at 816-479-5900 or info@midwesthemophilia.org.

Our Trivia Night Fundraiser continues to grow each year! Held in the Kansas City area and open to the public, our community, industry partners, and business sponsors there is no shortage of displays of knowledge, laughter, music, and food as teams battle for top bragging rights. Funds raised from entry fees, sponsorships, and individual donors support our academic scholarship and financial assistance programs. In 2021, we raised over \$6,000!! For sponsorship information of the 2022 Trivia Night, please contact us at 816-479-5900 or info@midwesthemophilia.org.



CAMP WILDERNESS SUMMER CAMP

.....

In its 30th year, Camp Wilderness is our most beloved and anticipated event held every summer for kids ages 7-17 who are diagnosed as carriers, with hemophilia, von Willebrand disease, and/or platelet disorders. Our camp mission is to provide campers with a fun, safe, and educational experience along with opportunities to build relationships with others diagnosed with similar bleeding disorders. Camp is a unique place where kids can discuss and share their experiences of living with a bleeding disorder and know that they are heard and understood. For some, it is the only opportunity to meet peers who also have bleeding disorders. Campers receive onsite medical care and education, including supervised self-infusion skills, healthy habits, and the benefits of maintaining an active lifestyle.

Unfortunately, the Covid-19 health crisis did not allow us to be at Lake Doniphan's retreat center this summer, so we "infused" a Camp Wilderness experience and showcase into Family Education Weekend in the fall where our youth and teens had the chance to play camp games, do woodworking and craft projects, receive health education, infusion support, and hang out around the "campfire". If you are interested in volunteering at Camp Wilderness in the summer of 2022, please email mhacampdirector@gmail.com.



COMMUNITY OUTREACH & EDUCATION DAYS

Providing bleeding disorders health education and information such as research, new or innovative treatment options, product information, programs and services offered through health-related resources are an imperative part of what MHA provides to our members. However, it can be a challenge as MHA's coverage area spans over 100,000 square miles. In order to reach as many people as possible, we host Education Days and Community Outreach Programs by traveling to pockets across Kansas and western Missouri where our members are located.

This year and most likely moving forward these programs will be offered in a variety of platforms and venues and gives us a chance to meet in-person and/or online. To find information or to register to attend future education programs, visit our website, midwesthemophilia.org and follow us on Facebook, Twitter, and Instagram.



ADVOCACY

Advocacy and awareness are essential aspects of support provided to our bleeding disorders community. Our advocacy committee and member representatives gather annually at both state and national levels to discuss important issues, needs and for access to care with elected officials and other government representatives. MHA collaborates with the Gateway Hemophilia Association in St. Louis, Missouri, to form the Missouri Bleeding Disorders Advocacy Coalition coming together in Jefferson City, Missouri, to address state issues. We also participate in the National Hemophilia Foundation's Washington Days in Washington D.C. along with representatives from the Hemophilia Federation of America and chapter leaders from across the United States.

We believe the most impactful way to advocate and bring awareness is when a community member shares their bleeding disorder story with the people they are connected to: a family member, friend, neighbor, teacher, coach, school nurse, doctor or anyone that may cross their path. Each time these experiences are told, another step towards better understanding, general support, and needs-awareness is achieved. We are always expanding our advocacy efforts in both Missouri and Kansas. If you or someone you know has had a positive or negative experience relative to access to healthcare, you want to share your bleeding disorder story, and/or you like to be part of the advocacy group, please email info@midwesthemophilia.org.



SCHOLARSHIP

From our inception as an organization, MHA has believed in the power of education. We want to encourage our community members to be productive citizens and one way to do that is through offering academic scholarships to assist with the cost of secondary learning.

The MHA Scholarship of \$1,000 has been offered for the past 26+ years and in 2016 another \$1,000 scholarship, the Mark Dudley Scholarship, was added in honor of a past board treasurer. These two scholarships combined have awarded over \$32,000 in educational funding.

MHA also offers the Georgia Northway Scholarship, which is managed by the Truman Heartland Community Foundation. The scholarship was established when MHA was named an estate beneficiary of Georgia Northway from the Wichita, Kansas area. Ms. Northway had two sons that had passed away due to complications from hemophilia. It was her wish that part of her estate be utilized to create a scholarship fund for individuals with bleeding disorders. Truman Heartland received \$423,924.87 in 2003 to start the scholarship. Each year, approximately 5% of the principal balance is available for scholarships, resulting in awards of \$313,188.44 in 118 scholarships to 44 students. The great part of the Georgia Northway Scholarship is that it is renewable. Recipients can re-apply each year, potentially receiving funding beyond freshman year.

Deadlines for all three scholarships are in late spring each year. Details and applications can be found on midwesthemophilia.org.

2021-2022 GEORGIA NORTHWAY SCHOLARSHIP RECIPIENTS:

*Moriah Bruening, William Carter, Ramsey Divine,
Elizabeth Hancock Alex Ince*

2021 MIDWEST HEMOPHILIA ASSOCIATION SCHOLARSHIP RECIPIENT:

Elijah Meadows

2021 MARK DUDLEY ACADEMIC SCHOLARSHIP RECIPIENT:

Alex Ince

FINANCIAL ASSISTANCE PROGRAM

Started in 2020, the Financial Assistance Program is a part of the continuing efforts to help improve the quality of life for our community members affected by bleeding disorders. The program provides funds to eligible individuals and families who may be experiencing unexpected hardship with expenses incurred in the care, treatment, or prevention of a bleeding disorder and basic living expenses. Through this new resource, MHA has provided over \$6,300 in assistance for fourteen families.

To be eligible for this program you must meet the following criteria:

- You must live within MHA's geographical service area of Kansas and western Missouri and/or be a current patient of the Kansas City Regional Hemophilia Treatment Center.
- You must be the parent or caregiver of a minor child who lives in your home and who has a diagnosis of a bleeding disorder; OR be an individual with a diagnosis of a bleeding disorder.
- You must have requested assistance from TWO (2) other agencies before applying to MHA and provide contact information for those agencies and the status of your requests.
- You must complete all sections of the application thoroughly and accurately.

Financial assistance depends on the availability of funds and applicant eligibility. Funding is not guaranteed. Applicants should allow at least two weeks for MHA to process their request. Assistance is limited to a maximum of \$500 per household. MHA assistance is limited to once every two years. In the presence of special circumstances, the MHA Board of Directors will review exceptional requests.

Disbursements will be made only to creditors identified in the application and that have been verified by MHA. No payments will be made directly to applicants.

Applications and information pertaining to funding requests are considered confidential but may be used for statistical purposes, and for compliance with local, state, federal or affiliate organization requirements. No personal information will be used or disclosed for any purpose other than that for which it was collected. At no time will personal information be shared with any individual, company or organization outside of MHA.

FINANCIAL ASSISTANCE PROGRAM REQUEST PROCESS:

1. Application forms are available by calling the MHA office at 816-479-5900, by emailing a request to info@midwesthemophilia.org, or by downloading the form at www.midwesthemophilia.org
2. Completed applications and a copy of the bill should be mailed to the MHA office: 1471 W. South St, Suite F, Ozark, MO 65721 OR emailed to info@midwesthemophilia.org
3. Application forms should be filled out by the applicant. If this is not possible and it is necessary for another person to fill/complete the application on behalf of the applicant, an MHA representative will contact the applicant before the application will be processed.
4. MHA staff will review applications for completeness, check references, and consider the date the funds are needed in order to determine urgency of the request.
5. Incomplete applications will be returned to the applicant with an explanation of why it was returned and a description of the information still required.
6. Complete applications will be sent to the Financial Assistance Review Committee in de-identified format.
7. If the application is approved, MHA staff will notify the applicant and payment will be issued to the creditor identified on the application.
8. If the application is disapproved, MHA staff will notify the applicant with an explanation.
9. MHA staff will update its Financial Assistance Program records and add the applicant to the MHA database for future reference/communication.

Note: This program is intended to help individuals and families who have exhausted all other sources of assistance and for whom no other funds are available.

Individual donations, grants, and fundraisers currently support this fund. Additional contributions can be made online via our website's yellow "Donate" button at midwesthemophilia.org or mailed to the physical office at 1471 W. South Street, Suite F, Ozark, MO 65721 OR to P.O. Box 412866, Kansas City, MO 64141.

Unite

for Bleeding Disorders



**SATURDAY,
OCTOBER 16, 2021**
10:00am - 1:00pm

Heritage Park, Shelter 1
16050 S Pflumm Road
Olathe, KS 66062



HEMOPHILIA
ALLIANCE

www.uniteforbleedingdisorders.org



CAN WE COUNT ON YOU?!

Each year, the Midwest Hemophilia Association hosts an annual Walk to bring together YOU, the bleeding disorders community of Kansas and Western Missouri, and your supporters to raise crucial funds for the organization!

Donations raised go directly to MHA to help us meet our mission: to improve the quality of life for those affected by bleeding disorders through education, advocacy, and support.

Because of you, those that follow in your footsteps will have access to resources and programs provided by your chapter!

Register your team today OR choose one of our MHA Teams listed and DONATE! Simply scan the QR code below! Be sure to download the app for easy fundraising!



REGISTER TODAY!

Visit www.uniteforbleedingdisorders.org and click "Find a Walk". Search for walks in Kansas. Once on the local page, click **REGISTER NOW** to form your team!



Family Education Weekend Agenda

Saturday, September 25

7:30-9:00am	Breakfast	Salon E
8:00-10:55am <i>*Make sure to visit our online exhibitors!</i>	WELCOME & ALL EXHIBITS OPEN	Grand Ballroom Foyer
	Camp Wilderness Tie-Dye Station (sizes not guaranteed, while supplies last)	
	Childcare: 0-4yrs Youth: K-5th Check-In	Quail Creek I-III
11:00am-12:00pm	<u>Opening Session:</u> Rising to Life's Challenges	Salon ABCD
12:00-1:00pm	Lunch & Sponsor Presentations	Salon E
1:00-1:55pm	<u>Break Out:</u> Nurturing Couple Relationships	Salon AB
	<u>Break Out (Spanish):</u> Put Yourself Out There: Sharing & Advocating for Bleeding Disorders	Salon CD
2:00-2:55pm	<u>Break Out:</u> Harness the Power of Joy	Salon AB
	<u>Break Out:</u> Spotlight On Siblings	Salon CD
3:00-3:30pm	Snack Break	



Family Education Weekend Agenda

Saturday, September 25 (continued)

3:30-4:25pm	<u>Break Out:</u> Gene Therapy Jeopardy	Salon AB
4:30-5:25pm	<u>Break Out:</u> Adversity, Strength, & Resilience	Salon AB
	<u>Break Out:</u> Pushing Through with Positivity	Salon CD
6:00pm	Dinner & Camp Wilderness Showcase	Grand Ballroom & Salons GHIJ

Sunday, September 26

8:00-9:15am	Breakfast: Chris Cakes!	Salon E
9:30am	<u>General Session:</u> Bleeding Prophylaxis: Who Needs It and Why We Recommend It	Salon E
10:30am	Awards & Recognition Ceremony	Salon E
11:30am	Dismiss: Hotel check-out, Childcare/Youth Pick-Up	



Thank You
To Our Sponsors!

GOLD SPONSORS



Bayer

CSL Behring
Biotherapies for Life™

B:OMARIN®

octapharma

For the safe and optimal use of human proteins

SOLEO
HEALTH®
Innovators in Specialty Infusion

SANOFI GENZYME



SILVER SPONSORS



ARJ Infusion
SERVICES



GRIFOLS


BRONZE SPONSORS



accredo



2020 ANNUAL REPORT



The Midwest Hemophilia Association supports the bleeding disorders communities in **KANSAS** and **WESTERN MISSOURI**.



Hemophilia is a rare inherited blood disorder affecting over 20,000 people in the U.S.



Midwest Hemophilia Association



NATIONAL HEMOPHILIA FOUNDATION
for all bleeding disorders



Midwest Hemophilia Association is a proud Member Organization of the Hemophilia Federation of America (HFA) and an affiliated chapter of the National Hemophilia Foundation (NHF).

500

Approximate number of people reached through MHA's annual programs & resources

Number of events hosted by MHA in 2020

22

Where It Comes From

Event & Media Sponsorships.....	\$107,050
Donations, Memorials & Grants.....	\$26,100
Fundraisers.....	\$31,650
Interest Income.....	\$9,100

Where It Goes

Education Services.....	\$80,920
Operation Costs.....	\$36,000
Support Services.....	\$12,980
Scholarships.....	\$22,000

Estimated Total Revenue: \$173,900
Estimated Total Expenses: \$151,900

HELPFUL NUMBERS

Kansas City Regional Hemophilia Center
1-816-302-6869 • 1-800-236-1713

**University Of Missouri Hospital & Clinics
Hemophilia Treatment Center**
1-573-882-9355

National Hemophilia Foundation (NHF)
1-800-42-HANDI • www.hemophilia.org

Hemophilia Federation Of America (HFA)
202-675-6984 • www.hemophiliafed.org

**Washington University
St. Louis, MO**
314-721-2084



**Delivering
quality and
compassionate
infusion care in
the comfort of
your own home.**

7930 Marshall Drive
Lenexa, KS 66214
866-451-8804
arjinfusion.com



Explore HEAD-TO-HEAD Pharmacokinetic (PK) Study Data

See half-life, clearance and other
PK data from the crossover study
comparing **Jivi®** and **Eloctate®**.

Visit **PKStudies.com** to find out more.

► **Pharmacokinetics** is the study of the activity
of drugs in the body over a period of time.

Jivi®
antihemophilic factor
(recombinant) PEGylated-auc1
LET'S GO

©2020 Bayer. All rights reserved. All trademarks are the property of their respective owner. Printed in the USA 0190 PP-JiviUS-1006-1



HemDifferently

Exploring the science behind gene therapy research

Gene therapy research has the potential to bring an entirely new option to people with specific genetic conditions. Many gene therapies are in clinical trials to evaluate the possible risks and benefits for a range of conditions, including hemophilia. HemDifferently is here with gene therapy education, providing accurate information in a way you can understand.

Let's explore gene therapy together at
HemDifferently.com

No gene therapies for hemophilia have been approved for use or determined to be safe or effective.

BioMARIN

©2020 BioMarin Pharmaceutical Inc. All Rights Reserved. MMRCGTH0037 0920

CSL Behring

Biotherapies for Life™

Proud to serve the bleeding disorders community with the latest technologies, innovative therapies and support.



Mike Appleseth

Manager, Coagulation Products

641-757-0499

mike.appleseth@cslbehring.com

Serving Iowa, Nebraska, Kansas and Missouri



Connected to you.

As Community Relations & Education Managers, we're united in our efforts to support and educate the hemophilia community.

SANOFI GENZYME

© 2021 Genzyme Corporation. All rights reserved. MAT-US-2101737-v1.0-03/2021



Reach out to your local
CoRe to learn more.
rareblooddisorders.com
@HemophiliaCoRes
1-855-SGZHEME

sign the 9 is now online!

Now it's easier than ever to make a difference.

Help make IXINITY® available to individuals in the United States who can't afford to be without it. It's easy. Just visit signthe9.com and fill out a brief form. When you do, **9 IU of IXINITY will be donated in your name**. While you're there, build your own one-of-a-kind 9. Add your name, share your 9 on social media...and watch the support grow!



► Scan me or visit
signthe9.com today!



MEDEXUS
PHARMA

Medexus Pharma, Inc., Chicago, IL 60606

IXINITY® (coagulation factor IX (recombinant)) and any and all Medexus Pharma, Inc. brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Medexus Pharma, Inc. in the United States and/or other countries.

© 2021 Medexus Pharma, Inc. All rights reserved. MP-IX-0399

IXINITY®
coagulation factor IX
(recombinant)

GO SEEK. GO EXPLORE.
GO AHEAD.

PEOPLE LIKE YOU. STORIES LIKE YOURS.
Explore more at HEMLIBRAjourney.com



Discover your sense of go. Discover HEMLIBRA.

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:

- **Thrombotic microangiopathy (TMA)**, a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
- **Blood clots (thrombotic events)**, which may form in blood vessels in your arm, leg, lung, or head

Please see Brief Summary of Medication Guide on following page for Important Safety Information, including **Serious Side Effects**.


HEMLIBRA®
emicizumab-kxwh | IMP
injection for subcutaneous use | IMP

Medication Guide HEMLIBRA® (hem-lee-bruh) (emicizumab-kxwh) injection, for subcutaneous use

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII (FVIII) and the recommended dose and schedule to use for breakthrough bleed treatment.

HEMLIBRA may cause the following serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including:

- **Thrombotic microangiopathy (TMA).** This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the following signs or symptoms during or after treatment with HEMLIBRA:
 - confusion
 - weakness
 - swelling of arms and legs
 - yellowing of skin and eyes
 - stomach (abdomen) or back pain
 - nausea or vomiting
 - feeling sick
 - decreased urination
- **Blood clots (thrombotic events).** Blood clots may form in blood vessels in your arm, leg, lung, or head. Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment with HEMLIBRA:
 - swelling in arms or legs
 - pain or redness in your arms or legs
 - shortness of breath
 - chest pain or tightness
 - fast heart rate
 - cough up blood
 - feel faint
 - headache
 - numbness in your face
 - eye pain or swelling
 - trouble seeing

If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

See “What are the possible side effects of HEMLIBRA?” for more information about side effects.

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

Hemophilia A is a bleeding condition people can be born with where a missing or faulty blood clotting factor (factor VIII) prevents blood from clotting normally.

HEMLIBRA is a therapeutic antibody that bridges clotting factors to help your blood clot.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant or plan to become pregnant. It is not known if HEMLIBRA may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with HEMLIBRA.
- are breastfeeding or plan to breastfeed. It is not known if HEMLIBRA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use HEMLIBRA?

See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

- Use HEMLIBRA exactly as prescribed by your healthcare provider.
- **Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.**
- **You may continue prophylactic use of FVIII for the first week of HEMLIBRA prophylaxis.**
- HEMLIBRA is given as an injection under your skin (subcutaneous injection) by you or a caregiver.

- Your healthcare provider should show you or your caregiver how to prepare, measure, and inject your dose of HEMLIBRA before you inject yourself for the first time.
- Do not attempt to inject yourself or another person unless you have been taught how to do so by a healthcare provider.
- Your healthcare provider will prescribe your dose based on your weight. If your weight changes, tell your healthcare provider.
- You will receive HEMLIBRA 1 time a week for the first four weeks. Then you will receive a maintenance dose as prescribed by your healthcare provider.
- If you miss a dose of HEMLIBRA on your scheduled day, you should give the dose as soon as you remember. You must give the missed dose as soon as possible before the next scheduled dose, and then continue with your normal dosing schedule. **Do not** give two doses on the same day to make up for a missed dose.
- HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.

What are the possible side effects of HEMLIBRA?

- See “What is the most important information I should know about HEMLIBRA?”

The most common side effects of HEMLIBRA include:

- redness, tenderness, warmth, or itching at the site of injection
- headache
- joint pain

These are not all of the possible side effects of HEMLIBRA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store HEMLIBRA?

- Store HEMLIBRA in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.
- Store HEMLIBRA in the original carton to protect the vials from light.
- Do not shake HEMLIBRA.
- If needed, unopened vials of HEMLIBRA can be stored out of the refrigerator and then returned to the refrigerator. HEMLIBRA should not be stored out of the refrigerator for more than a total of 7 days or at a temperature greater than 86°F (30°C).
- After HEMLIBRA is transferred from the vial to the syringe, HEMLIBRA should be used right away.
- Throw away (dispose of) any unused HEMLIBRA left in the vial.

Keep HEMLIBRA and all medicines out of the reach of children.

General information about the safe and effective use of HEMLIBRA.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use HEMLIBRA for a condition for which it was not prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about HEMLIBRA that is written for health professionals.

What are the ingredients in HEMLIBRA?

Active ingredient: emicizumab-kxwh

Inactive ingredients: L-arginine, L-histidine, poloxamer 188, and L-aspartic acid.

Manufactured by: Genentech, Inc., A Member of the Roche Group,
1 DNA Way, South San Francisco, CA 94080-4990

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
U.S. License No. 1048

For more information, go to www.HEMLIBRA.com or call 1-866-HEMLIBRA.
This Medication Guide has been approved by the U.S. Food and Drug Administration
Revised: 10/2018



HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The HEMLIBRA logo is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The Genentech logo is a registered trademark of Genentech, Inc.
All other trademarks are the property of their respective owners.
©2020 Genentech USA, Inc. All rights reserved. M-US-00007357(v1.0) 09/20

Genentech
A Member of the Roche Group



Bleeding Disorder Solutions

We provide our bleeding disorder patients with a comprehensive and customizable care plan that focuses on their overall quality of life and gettign them back to the things they love most.

Learn more about our specialty pharmacy services at [**paragonhealthcare.com/hemo**](https://paragonhealthcare.com/hemo)



[PARAGONHEALTHCARE.COM/HEMO](https://paragonhealthcare.com/hemo)

P: 833.862.4559

F: 855.862.4373



A **ONCE-WEEKLY** TREATMENT OPTION FOR HEMOPHILIA B.

HOW DOES
THIS FACTOR IN?

To find out about a prescription
option, talk to your doctor or visit
OnceWeeklyForHemophiliaB.com


PP-HEM-USA-1424-01

© 2021 Pfizer Inc.

All rights reserved.

February 2021





WE'RE IN THIS TOGETHER.

Thursday 3:24 pm

Practicing yoga with her mom

Mariana, living with von Willebrand disease

Not an actual patient

Let's make today brilliant.

Takeda is here to support you throughout your journey and help you embrace life's possibilities. Our focus on factor treatments and educational programs, and our dedication to the bleeding disorders community, remain unchanged. And our commitment to adult patients with von Willebrand disease is stronger than ever.

*Not all activities are appropriate for all individuals.
Consult your doctor prior to engaging in any activity.*

 bleedingdisorders.com | 

Copyright © 2020 Takeda Pharmaceutical Company Limited. All rights reserved. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. US-NON-1141v1.0 06/20

NUWIQ®

Antihemophilic Factor
(Recombinant)

www.NUWIQUUSA.com

wilate®

von Willebrand
Factor/Coagulation
Factor VIII Complex
(Human)

www.wilateusa.com



Resources for patients & caregivers, support for those navigating care, reliable educational materials, and uplifting community connection.

Factor My Way Assistance

Free trial, co-pay assistance, and real-world insurance know-how for eligible patients.

Factor My Way Connection

Meet experts and join our online support community to help you access resources and build relationships.

Factor My Way Events

Join scheduled live and on-demand digital information programs and events.

Factor My Way Learning

Learn-as-you-go, practical information about bleeding disorders, treatment, and lifestyle management.



Join Today!



factormyway.com

For personalized assistance, contact your local Octapharma Representative:



Kristin Marema

Patient Experience Manager

Phone | 201.850.3686

E-mail | Kristin.Marema@octapharma.com

©2021. Octapharma USA Inc. All rights reserved.
Date of preparation: 8/2021. NUW-0415-CAD

octapharma



1471 W. South Street
Suite F
Ozark, MO 65721



Follow us on Facebook
MidwestHemophiliaAssociation



Follow us on Twitter
MidwestHemophi1



Follow us on Instagram
MidwestHemophiliaAssociation